These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36250711)

  • 41. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.
    Zivadinov R; Bergsland N; Korn JR; Dwyer MG; Khan N; Medin J; Price JC; Weinstock-Guttman B; Silva D;
    AJNR Am J Neuroradiol; 2018 Feb; 39(2):289-295. PubMed ID: 29170269
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of the genetic contribution to brain magnetic resonance imaging lesion load and atrophy measures in multiple sclerosis patients.
    Clarelli F; Assunta Rocca M; Santoro S; De Meo E; Ferrè L; Sorosina M; Martinelli Boneschi F; Esposito F; Filippi M
    Eur J Neurol; 2021 Aug; 28(8):2513-2522. PubMed ID: 33864731
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
    Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI.
    Parra Corral MA; Govindarajan ST; Stefancin P; Bangiyev L; Coyle PK; Duong TQ
    Mult Scler Relat Disord; 2019 Jun; 31():74-81. PubMed ID: 30951968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brain Morphometry Estimation: From Hours to Seconds Using Deep Learning.
    Rebsamen M; Suter Y; Wiest R; Reyes M; Rummel C
    Front Neurol; 2020; 11():244. PubMed ID: 32322235
    [No Abstract]   [Full Text] [Related]  

  • 48. Automated separation of diffusely abnormal white matter from focal white matter lesions on MRI in multiple sclerosis.
    Maranzano J; Dadar M; Zhernovaia M; Arnold DL; Collins DL; Narayanan S
    Neuroimage; 2020 Jun; 213():116690. PubMed ID: 32119987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.
    Datta S; Staewen TD; Cofield SS; Cutter GR; Lublin FD; Wolinsky JS; Narayana PA; ;
    Mult Scler Relat Disord; 2015 Mar; 4(2):124-36. PubMed ID: 25787188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Quantitative Imaging Biomarker Supporting Radiological Assessment of Hippocampal Sclerosis Derived From Deep Learning-Based Segmentation of T1w-MRI.
    Rebsamen M; Radojewski P; McKinley R; Reyes M; Wiest R; Rummel C
    Front Neurol; 2022; 13():812432. PubMed ID: 35250818
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study.
    Fox J; Kraemer M; Schormann T; Dabringhaus A; Hirsch J; Eisele P; Szabo K; Weiss C; Amann M; Weier K; Naegelin Y; Kappos L; Gass A
    Int J Mol Sci; 2016 Apr; 17(4):489. PubMed ID: 27043553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deep learning-based methods may minimize GBCA dosage in brain MRI.
    Luo H; Zhang T; Gong NJ; Tamir J; Venkata SP; Xu C; Duan Y; Zhou T; Zhou F; Zaharchuk G; Xue J; Liu Y
    Eur Radiol; 2021 Sep; 31(9):6419-6428. PubMed ID: 33735394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal changes of deep gray matter shape in multiple sclerosis.
    Tsagkas C; Geiter E; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Granziera C; Mallar Chakravarty M; Magon S
    Neuroimage Clin; 2022; 35():103137. PubMed ID: 36002960
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI.
    Meier DS; Guttmann CRG; Tummala S; Moscufo N; Cavallari M; Tauhid S; Bakshi R; Weiner HL
    J Neuroimaging; 2018 Jan; 28(1):36-47. PubMed ID: 29235194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes.
    Ceccarelli A; Rocca MA; Pagani E; Colombo B; Martinelli V; Comi G; Filippi M
    Neuroimage; 2008 Aug; 42(1):315-22. PubMed ID: 18501636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging.
    Vavasour IM; Sun P; Graf C; Yik JT; Kolind SH; Li DK; Tam R; Sayao AL; Schabas A; Devonshire V; Carruthers R; Traboulsee A; Moore GW; Song SK; Laule C
    Mult Scler; 2022 Mar; 28(3):418-428. PubMed ID: 34132126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measurement of the permeability, perfusion, and histogram characteristics in relapsing-remitting multiple sclerosis using dynamic contrast-enhanced MRI with extended Tofts linear model.
    Yin P; Xiong H; Liu Y; Sah SK; Zeng C; Wang J; Li Y; Hong N
    Neurol India; 2018; 66(3):709-715. PubMed ID: 29766930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
    Kjølhede T; Siemonsen S; Wenzel D; Stellmann JP; Ringgaard S; Pedersen BG; Stenager E; Petersen T; Vissing K; Heesen C; Dalgas U
    Mult Scler; 2018 Sep; 24(10):1356-1365. PubMed ID: 28752800
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis.
    Chu R; Tauhid S; Glanz BI; Healy BC; Kim G; Oommen VV; Khalid F; Neema M; Bakshi R
    J Neuroimaging; 2016; 26(1):62-7. PubMed ID: 26118637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MRI-Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis.
    Platten M; Martola J; Fink K; Ouellette R; Piehl F; Granberg T
    J Neuroimaging; 2020 Mar; 30(2):198-204. PubMed ID: 31750599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.